Adherence as a particular issue with protease inhibitors
- 1 January 1997
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 8, 10-17
- https://doi.org/10.1016/s1055-3290(97)80003-9
Abstract
Suboptimal therapeutic doses of HIV protease inhibitors lead to the emergence of drug resistance and reduced drug efficacy. It is imperative, then, that patients and clinicians alike are fully educated about the importance of patients taking all the pills in these new, admittedly complex, antiretroviral regimens. With protease inhibitors especially, missing doses and/or taking drug holidays or partial doses will mean the rapid emergence of HIV isolates that are resistant to these drugs.Keywords
This publication has 8 references indexed in Scilit:
- The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic MillimeterNew England Journal of Medicine, 1996
- Human Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing PhenotypeThe Journal of Infectious Diseases, 1996
- Virologic and Immunologic Benefits of Initial Combination Therapy with Zidovudine and Zalcitabine or Didanosine Compared with Zidovudine MonotherapyThe Journal of Infectious Diseases, 1996
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996
- Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic MillimeterNew England Journal of Medicine, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and TherapyScience, 1995